Latest Recruitment News

LGI Limited posted a robust FY26 with a 35.5% rise in net profit, underpinned by a 33% jump in biogas flows and a $56 million capital raise fueling expansion beyond 80MW.

Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.

Emyria has cleared a key operational hurdle by resolving Authorised Prescriber capacity constraints in Perth and Queensland, enabling a planned expansion of treatment days in Q4 2026 through the recruitment of 15 new therapists.

Lindian Resources confirms Kangankunde Rare Earths Project remains on track for first production in late 2026, with concurrent progress across construction, mining, and operational readiness. The company is expanding its operational footprint internationally and strengthening its team to support the transition from construction to production.

Recce Pharmaceuticals has secured ethics approval to add an active-controlled arm to its pivotal Phase 3 trial of RECCE® 327 Topical Gel for diabetic foot infections in Australia, enabling head-to-head comparison against existing antibiotics.

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

NextEd Group navigated a tough international education market in FY26, boosting underlying EBITDA by 7% to $15.3 million even as revenue fell 6.7%. A $13 million goodwill impairment weighed on net losses, but ongoing cost discipline and vocational course growth underpin a resilient platform.

HiTech Group Australia posted a 3.2% revenue decline in FY26 to $65.6 million, with EBITDA down 35%, yet maintains a strong balance sheet and a 4 cent fully franked dividend. The company is progressing its acquisition of Hudson’s Australian operations, aiming to bolster growth and margins in FY27.

Ignite Limited reported an 18.8% drop in revenue to $73.2 million and a 29.4% fall in statutory profit to $0.87 million for FY2026, while maintaining a 13% gross margin and declaring a fully franked final dividend.

Microequities Asset Management Group saw a 20.1% drop in profit after tax for FY26, hit by sharp valuation falls in tech-heavy portfolios amid AI fears, despite a 1.5% revenue rise and a strong balance sheet.

Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.

Dimerix CEO Dr Nina Webster detailed the company’s geographic and product diversification at the Bioshares Summit, spotlighting the commercial potential of DMX-200 and the newly acquired Phase 2 asset DMX-652 targeting acute kidney injury.